Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis
about
Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistanceFree fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolismSelective Insulin Resistance in the KidneyThe association between PGC-1α and Alzheimer's diseaseEmerging evidence for beneficial macrophage functions in atherosclerosis and obesity-induced insulin resistanceBioactive Plant Metabolites in the Management of Non-Communicable Metabolic Diseases: Looking at Opportunities beyond the HorizonLessons from mouse models of high-fat diet-induced NAFLDNotch signaling as a novel regulator of metabolismt-10, c-12 CLA dietary supplementation inhibits atherosclerotic lesion development despite adverse cardiovascular and hepatic metabolic marker profilesInsulin signaling regulates fatty acid catabolism at the level of CoA activationHow Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Nonalcoholic fatty liver disease - A multisystem disease?Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylationFoxO1 mediates insulin-dependent regulation of hepatic VLDL production in miceParameter trajectory analysis to identify treatment effects of pharmacological interventionsImpaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoproteinCarcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolismTreatment of nonalcoholic fatty liver disease: role of AMPK.Fructose: it's "alcohol without the buzz".PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis.The metabolic syndromeAblation of ARNT/HIF1beta in liver alters gluconeogenesis, lipogenic gene expression, and serum ketonesViewpoints on the way to a consensus session: where does insulin resistance start? The liver.Deficiency of oncostatin M receptor β (OSMRβ) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice.Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acidsBifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesisA minor role for lipocalin 2 in high-fat diet-induced glucose intolerance.Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse.Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation.Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice.Mice deficient in group VIB phospholipase A2 (iPLA2gamma) exhibit relative resistance to obesity and metabolic abnormalities induced by a Western diet.Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulationHepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemiaFoxO1 links hepatic insulin action to endoplasmic reticulum stress.Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state.Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B.Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome
P2860
Q24648189-4F48990B-9514-4D1C-85B1-13E68D509D64Q24810354-6320CF86-34D3-4FDD-B4B5-E4D978049FAEQ26744243-CBA0E51E-E3DE-45ED-832E-473E53C49818Q26751165-22038A15-8F17-4A1A-BD28-9D0F74C04E58Q26768878-9D67A7F5-1A59-41F3-9AAA-E86D6935C6E5Q26771980-FA37F805-3DDE-4CED-8071-6FE64B8A5ED8Q26829532-18855C81-5908-4356-BF17-E5FB14B3C2C4Q27014152-1C31F639-16EB-4A9F-8E05-58597E0389F5Q27324291-86A59F0F-2383-4B10-AB8A-38747C9FE979Q27334898-B45FB806-BE03-4FA7-84C8-9BFE7FC54C81Q28074455-2B03F6B3-F26A-46C5-B235-0B33C912C861Q28079077-893BB7AE-8AEF-4118-8865-F00E1AFE367DQ28272571-33837EE0-42A4-45C1-B6FE-302A8A9A319EQ28507185-E3A9A1FE-D73B-4CD3-8821-6C632C981E24Q28507512-2037A244-1515-4F9B-8821-A333FDC74A00Q28535030-EDB8CB5A-3DEB-436F-812F-A5452F546365Q28583188-A7FCE83C-B054-4B1C-81DE-6787AAE85160Q28591917-CBDD1A88-4D73-4572-8EF1-87B350DD4986Q30248230-3D2631EE-A95F-4BE7-AF50-CDD549429080Q30428239-47A0E565-C8DF-4895-A740-ABFF3651F294Q33564184-538D95FA-B34B-491A-91AC-47B0AE043D7DQ33569142-95046710-FAEC-4AB1-A4C1-065E033B0D6EQ33577124-E889B954-5FFA-4F2C-A36E-EFCFEE843D71Q33610786-0A498E3E-1930-412B-8AEF-3883C35C4BC5Q33619351-947AC6FB-C9A1-441D-AD64-73799EADA137Q33688639-5EBE180E-F509-4026-AEBD-F4586C53C456Q33734679-BFAB4A16-B288-4F7C-966D-2FCA76394683Q33816671-C71EFE8C-A235-40A0-9BCE-79812AFD201BQ33848311-37A401D6-5E5C-4D5E-940F-09855328403FQ33865096-25A59341-8A27-46F8-97B0-895EA1183EA1Q33867427-6859F8A5-C56F-4B38-8DD2-4BC6F99D5CB4Q33869748-9EB6AD05-3D6A-4B40-8842-3BB6174C19E6Q33916535-40056919-CE6D-4B46-A72A-7CBAC4508C60Q34037347-BFEEB794-2922-45DF-8310-111C124B2E46Q34089899-9FB72CEA-7DED-4DAD-8ADF-00FC9498A05DQ34094336-BCE88B97-97A2-43E8-92E8-FD058F0BB867Q34132566-53B8EE59-45D5-4F7B-AD93-2761B0F6FE6EQ34155467-2CF41D30-777E-41D1-8F13-A725570AECE7Q34212081-0C6453A2-9D56-4616-97A5-57F091C4F227Q34227893-4565EEA4-E006-441E-8F2D-38A3D5E8DB9D
P2860
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@ast
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@en
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@nl
type
label
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@ast
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@en
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@nl
prefLabel
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@ast
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@en
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@nl
P2093
P2860
P921
P1433
P1476
Hepatic insulin resistance is ...... ceptibility to atherosclerosis
@en
P2093
Antonio Hernandez-Ono
C Ronald Kahn
Christian Rask-Madsen
David E Cohen
Erez F Scapa
George L King
Gregory Stephanopoulos
Henry N Ginsberg
Joel T Haas
Martin C Carey
P2860
P304
P356
10.1016/J.CMET.2007.11.013
P577
2008-02-01T00:00:00Z